Compare KLTR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | CRDL |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.8M | 226.6M |
| IPO Year | 2021 | 2017 |
| Metric | KLTR | CRDL |
|---|---|---|
| Price | $1.40 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.50 | ★ $8.42 |
| AVG Volume (30 Days) | 202.0K | ★ 1.5M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $180,854,000.00 | N/A |
| Revenue This Year | $1.74 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $1.06 | $0.88 |
| 52 Week High | $2.05 | $2.34 |
| Indicator | KLTR | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 21.30 |
| Support Level | $1.32 | $0.96 |
| Resistance Level | $1.53 | $1.35 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 100.00 | 0.68 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.